Transforming the way we prevent and treat chronic lifestyle diseases.
A Little Of Our Story
SiPore15TM
SiPore15™ is a breakthrough particle for the safe reduction of blood sugar levels in people at risk of developing diabetes, prediabetics, and newly diagnosed type 2 diabetics. The device is a tasteless and odourless white powder taken with water. Upon its approval, SiPore15™ will be the first therapy for people with higher than normal blood sugar, with the potential to prevent type 2 diabetes.
SiPore15™ is Sigrid Therapeutics’ lead product candidate in clinical development, originating from research at Stockholm University and Karolinska Institute.

A Little Of Our Story
About Us
Lifestyle diseases, caused by poor diet and physical inactivity among others, are rising rapidly worldwide. Each year, 70% of all deaths globally – 40 million – are attributed to lifestyle diseases such as obesity, type 2 diabetes and heart disease.
Sigrid is a clinical-stage biotech Company driven by the vision to improve human health through material based innovations. We are pioneering a new class of engineered materials to prevent and treat lifestyle disease more safely than existing solutions on the market.
A Little Of Our Story
How does it work?
SiPore15™ is not absorbed into the body, but works locally in the gut in a novel way. Watch our video to learn more about how SiPore15™ works and its benefits.
”All Disease Begins in the Gut
HippocratesThe Father of Medicine
RESEARCH COLLABORATIONS



